Hematological Oncology 2007: Vol 25 Index & Table of Contents

2007·0.23 MB·English

Hematological Oncology mterScieiice*
Hematol Oncol 2007; 25: 212
AUTHOR INDEX VOLUME 25
Adam, E., 143 De Ponte, C., 164 Kok, K., 21 Poros, A., 143
Arpad, I., 178 Deak, L., 90 Kokoris, S. 1., 127 Pruneri, G., 184
Agnelli, L., 6 Del Fabro, V., 164 Kontopidou, F N., 127
Ahmed. S., 11 DeWitt, B., 11 Kopper, L., 90 Quartarone. E., 164
Aigner, T., 140 Diepstra, A., 21 Korkolopoulou, P, 127
Alati, C., 164 Dimitriadou, E. M., 127 Kozma, A., 143 Radaelli, F, 115
Allegra, A., 164 Dimopoulou, M. N., 127 Kyrtsonis, M.-C., 127 Rashid, 1., 189
Alonci. A., 164 Dorado, G., 30 Kiippens. R., 21 Raspadori, D., 38
Alterini, R., 198 Reiniger, L., 90
Andrikovics, H., 143 El-Sherbiny, M., 121 Rigacci, L., 198
L6pez-Pedrera, C., 30
Angelopoulou, M. K., 127 Ely, S., 16 Robbiani, D. F., 16
Lambertenghi-Deliliers, G.,
Aref, S., 121 Ely, S., 16 Ronchetti, D., 6
6
Atayar, <^., 21 Ruf, L.. 170
Lenoci, M., 38
Azmy, E., 121 Fabris. S., 6 Russo, D., 38
Leoni, F, 1
Falco, C., 84
Lombardi, L., 6
Bodor, C., 90 Fanin, R., 38 Sawada, M., 107
Luminari, S., 189
Balogh. Z., 90 Federico, M., 189 Schmittel, A., 132
Barbarroja. N., 30 Fenk, R., 170 Schwartz, A., 11
Barbazza. R., 184 Ferrara. F, 1, 84 Maiorana, A., 189 Schwarz, R.. 140
Barbolini, E., 189 Focosi, D., 96 Mammi, C., 189 Sessa, C., 53
Bari, A., 189 Foley, K. F, 96 Mansy, S., 121 Shimizu, M., 107
Barta. A., 143 Mappa, S., 198 Siakantaris, M., P, 127
Bellei, M., 189 Gagyi, A., 90 Marcheselli, L., 189 Siehl, J. M., 132
Bellomo, G., 164 Germing. U., 170 Martin, V., 184 Siendones, E., 30
Bergsagel, P. L., 16 Gitterman, L., 11 Martinelli, G., 184 Sirotti. M. A., 189
Bemardi. F., 198 Goda, T.. 121 Matolcsy, A., 90 Smith, K.. 11
Bertoni. F., 184 Gospodarowicz, M. K.. 11 Maur, M., 53 Sun, A., 11
Blokzijl, T., 21 Goto, N., 107 Mazzucchelli, L., 184 Szelenyi, H., 132
Boleti. E., 157 Gozzetti, A., 38 McMullin, M. F, 58 Szepesi, A., 90
Bonacorsi, G., 189 Graef, T., 170 Michelutti. A., 38 Szilvasi, A., 143
Bors. A., 143 Gyorgy, S., 178 Milani, K.. 184
Bosi, A.. 198 Min, W.-S., 76 Takami, T., 107
Bramanti. S., 115 Haag. J., 140 Montanini, A.. 189 Tambaro, F. R. 84
Buckley, C.-A., 11 Haas. R.. 170 Moriwaki. H., 107 Thiel. E.. 132
Buendia, P, 30 Hara. T., 107 Motta, T., 184 Tibiletti, M. G., 184
Harms, G.. 21 Mueller. S., 140 Tiribelli, M.. 38
Calistri, E., 38 Heaney, N. B., 66 Musolino, C.. 164 Tordai, A., 143
Calori, R., 115 Htxlgson. D. C., 11 Torres. A., 30
Candoni, A., 38 Holyoake. T. L.. 66 Torres. L. A.. 30
Nahajevszky. S., 143
Capella. C., 184 Hiitter, G., 132 Tsaftaridis, R, 127
Nassi, L., 198
Carrai, V.. 198 Tsang, R. W., 11
Nastro, E., 164
Celentano, M., 1 Intini, D., 6 Tsurumi, H., 107
Neri, A., 6
Cesaretti, M., 189 lurlo. A., 115
Niedobitek G.. 140
Chesi. M., 16 Izzo, B., 1 van den Berg, A., 21
Nobili. L., 6
Chiarvesio. A., 38 van der Vlies, R, 21
Choi. Y.. 76 Jeong, H.-Y., 76 Vassilakoptrulos. T. R, 127
Cicciu, D., 164 Johnson. P. W. M.. 157 Omer. N., 121 Vaupel. M., 170
Ciceri, G., 6 Judit, V., 178 Osman. E.. 121 Velasco. F, 30
Ciolli, S., 1 Oteri. G.. 164 Vicari, L.. 1, 84
Colombi. M., 115 Kiippers, R., 21 Viola. A., 1. 84
Colon, K., 16 Kajtar, B., 143 Palmieri, S., 1. 84
Copia. C., 84 Kalpadakis, C., 127 Pane, F. 1 Wells, W.. 11
Correale. P, 84 Kanemura. N., 107 Pangalis. G. A., 127
Cortelazzo, S., 184 Kasahara, S., 107 Partesotti, G., 189 Yamada. T., 107
Crump, M., 11 Kast. R. E.. 96 Pennese. E.. 189 Yasuda. 1.. 107
Csomor, J., 90 Katalin. K., 178 Pfeil, 1.. 21
Keilholz. U., 132 Pinotti. G., 184 Zanella. A., 115
D'Amico. M. R., 1, 84 Kim. C.-C., 76 Pintilie. M., 11 Zilioli, V. R , 115
D'Elia. R.. 84 Kim, H.-J., 76 Plata, E., 127 Zohren, F, 170
Damiani, D., 38 Kluiver. J.. 21 Pollio, F, 1 Zsofia. M., 178
de Jong, D., 21 Kobbe. G., 170 Poppema. S., 21 Zucca. E., 184
Copyright © 2007 John Wiley & Sons. Ltd.
Hematological Oncology mterScieiice*
Hematol Oncol 2007; 25: 212
AUTHOR INDEX VOLUME 25
Adam, E., 143 De Ponte, C., 164 Kok, K., 21 Poros, A., 143
Arpad, I., 178 Deak, L., 90 Kokoris, S. 1., 127 Pruneri, G., 184
Agnelli, L., 6 Del Fabro, V., 164 Kontopidou, F N., 127
Ahmed. S., 11 DeWitt, B., 11 Kopper, L., 90 Quartarone. E., 164
Aigner, T., 140 Diepstra, A., 21 Korkolopoulou, P, 127
Alati, C., 164 Dimitriadou, E. M., 127 Kozma, A., 143 Radaelli, F, 115
Allegra, A., 164 Dimopoulou, M. N., 127 Kyrtsonis, M.-C., 127 Rashid, 1., 189
Alonci. A., 164 Dorado, G., 30 Kiippens. R., 21 Raspadori, D., 38
Alterini, R., 198 Reiniger, L., 90
Andrikovics, H., 143 El-Sherbiny, M., 121 Rigacci, L., 198
L6pez-Pedrera, C., 30
Angelopoulou, M. K., 127 Ely, S., 16 Robbiani, D. F., 16
Lambertenghi-Deliliers, G.,
Aref, S., 121 Ely, S., 16 Ronchetti, D., 6
6
Atayar, <^., 21 Ruf, L.. 170
Lenoci, M., 38
Azmy, E., 121 Fabris. S., 6 Russo, D., 38
Leoni, F, 1
Falco, C., 84
Lombardi, L., 6
Bodor, C., 90 Fanin, R., 38 Sawada, M., 107
Luminari, S., 189
Balogh. Z., 90 Federico, M., 189 Schmittel, A., 132
Barbarroja. N., 30 Fenk, R., 170 Schwartz, A., 11
Barbazza. R., 184 Ferrara. F, 1, 84 Maiorana, A., 189 Schwarz, R.. 140
Barbolini, E., 189 Focosi, D., 96 Mammi, C., 189 Sessa, C., 53
Bari, A., 189 Foley, K. F, 96 Mansy, S., 121 Shimizu, M., 107
Barta. A., 143 Mappa, S., 198 Siakantaris, M., P, 127
Bellei, M., 189 Gagyi, A., 90 Marcheselli, L., 189 Siehl, J. M., 132
Bellomo, G., 164 Germing. U., 170 Martin, V., 184 Siendones, E., 30
Bergsagel, P. L., 16 Gitterman, L., 11 Martinelli, G., 184 Sirotti. M. A., 189
Bemardi. F., 198 Goda, T.. 121 Matolcsy, A., 90 Smith, K.. 11
Bertoni. F., 184 Gospodarowicz, M. K.. 11 Maur, M., 53 Sun, A., 11
Blokzijl, T., 21 Goto, N., 107 Mazzucchelli, L., 184 Szelenyi, H., 132
Boleti. E., 157 Gozzetti, A., 38 McMullin, M. F, 58 Szepesi, A., 90
Bonacorsi, G., 189 Graef, T., 170 Michelutti. A., 38 Szilvasi, A., 143
Bors. A., 143 Gyorgy, S., 178 Milani, K.. 184
Bosi, A.. 198 Min, W.-S., 76 Takami, T., 107
Bramanti. S., 115 Haag. J., 140 Montanini, A.. 189 Tambaro, F. R. 84
Buckley, C.-A., 11 Haas. R.. 170 Moriwaki. H., 107 Thiel. E.. 132
Buendia, P, 30 Hara. T., 107 Motta, T., 184 Tibiletti, M. G., 184
Harms, G.. 21 Mueller. S., 140 Tiribelli, M.. 38
Calistri, E., 38 Heaney, N. B., 66 Musolino, C.. 164 Tordai, A., 143
Calori, R., 115 Htxlgson. D. C., 11 Torres. A., 30
Candoni, A., 38 Holyoake. T. L.. 66 Torres. L. A.. 30
Nahajevszky. S., 143
Capella. C., 184 Hiitter, G., 132 Tsaftaridis, R, 127
Nassi, L., 198
Carrai, V.. 198 Tsang, R. W., 11
Nastro, E., 164
Celentano, M., 1 Intini, D., 6 Tsurumi, H., 107
Neri, A., 6
Cesaretti, M., 189 lurlo. A., 115
Niedobitek G.. 140
Chesi. M., 16 Izzo, B., 1 van den Berg, A., 21
Nobili. L., 6
Chiarvesio. A., 38 van der Vlies, R, 21
Choi. Y.. 76 Jeong, H.-Y., 76 Vassilakoptrulos. T. R, 127
Cicciu, D., 164 Johnson. P. W. M.. 157 Omer. N., 121 Vaupel. M., 170
Ciceri, G., 6 Judit, V., 178 Osman. E.. 121 Velasco. F, 30
Ciolli, S., 1 Oteri. G.. 164 Vicari, L.. 1, 84
Colombi. M., 115 Kiippers, R., 21 Viola. A., 1. 84
Colon, K., 16 Kajtar, B., 143 Palmieri, S., 1. 84
Copia. C., 84 Kalpadakis, C., 127 Pane, F. 1 Wells, W.. 11
Correale. P, 84 Kanemura. N., 107 Pangalis. G. A., 127
Cortelazzo, S., 184 Kasahara, S., 107 Partesotti, G., 189 Yamada. T., 107
Crump, M., 11 Kast. R. E.. 96 Pennese. E.. 189 Yasuda. 1.. 107
Csomor, J., 90 Katalin. K., 178 Pfeil, 1.. 21
Keilholz. U., 132 Pinotti. G., 184 Zanella. A., 115
D'Amico. M. R., 1, 84 Kim. C.-C., 76 Pintilie. M., 11 Zilioli, V. R , 115
D'Elia. R.. 84 Kim, H.-J., 76 Plata, E., 127 Zohren, F, 170
Damiani, D., 38 Kluiver. J.. 21 Pollio, F, 1 Zsofia. M., 178
de Jong, D., 21 Kobbe. G., 170 Poppema. S., 21 Zucca. E., 184
Copyright © 2007 John Wiley & Sons. Ltd.
Hematological Oncology .**. 4W1LEY
mterScience*
Hematol Oncol 2007; 25: 213
KEYWORD INDEX VOLUME 25
absolute count, 76 induction chemotherapy, 76
Acute Leukaemia, 58 inflammation, 96
acute myeloid leukaemia, 1, 38 Int feron, 58
acute myeloid leukemia, 84 interleukin-2 receptor alpha. 76
age, 84 IRAKI. 21
Akt, 30
allogeneic HSCT, 170 jaws, 164
AML, 30. 76, 121, 170
angiogenesis, 164 late complications. 178
antibiotics. 184 liposomal doxorubicin, 132. 198
API2. 184
array-based CGH, 21 maf, 16
autologous transplantation. 1 MALT, 184
MALTl. 184
B-cell lymphoma, 157 MAP kinases. 30
bcr-abl, 66 marginal zone. 184
BCR-ABL ela2 and el9a2 breakpoints, 143 marginal zone lymphoma. 127
biologically active dose. 53 MDS, 170
bisphosphonates. 164 mediastinum. 157
bone disease. 16 MMP-2. 121
mobilization. 84
molecular classification. 16
cardiomyopathy, %
multidrug resistance, 38
cardiovascular risk factors, 115
multiple myeloma. 6. 132. 164
CD45-t-CD25-l- cells. 76
Myelofibrosis. 58
chemotherapy, 11
myeloma, 16
CHOP, 107
chronic myelogenous leukaemia. 143
chronic myeloid leukaemia. 66 non-Hodgkin’s lymphoma, 107, 189, 198
CLL with increased prolymphocytes (CLL/PL). 90 normal karyotype, 38
clonal evolution. 90
osteonecrosis, 164
doxorubicin. 96, 198 osteofKjntin, 16
drug therapy, 66
phase 1 studies, 53
early clinical studies, 53 pirarubicin, 107
EBV. 140 Polycythaemia vera, 58
elderly. 107 ptopulation-based study, 189
endothelial cells, 164 primary mediastinal B-cell lymphoma, 157
epidemiology, 189 prognosis, 38. 121
Essential Thrombocythemia, 115 prognosis factors, 170
prognostic relevance, 1
protease inhibitors. 96
fertility, 11
FISH. 184
Ras mutation, 6
Flt3, 30
remission, 170
FLT3 mutations, 1
rituximab, 127
FSCNl, 21
SAGE. 21
gout. 140 senile lymphoproliferative disorder. 140
splenic. 127
haemopoietic stem cell, 66 STAT, 30
haemorrhagic complications, 115 stem cells, 84
hodgkin lymphoma, 11 stomach. 184
Hodgkin lymphoma, 21 surrogate biomarker endpoint, 53
Htxlgkin’s lymphoma, 178, 189 surrogate tissues, 53
HR-CGH. 90 survival, 30
Hydroxycarbamide, 58
TC classification. 6
IgVH gene. 90 THP-COP, 107
imatinib, 143 Thromboembolic agents. 58
imatinib mesylate. 66 thrombotic events. 115
imatinib resistance. 66 toxicity, 11
immunology, 157 treatment, 127, 132, 157, 178
incidence, 189 tyrosine kinase inhibitors, 66
Copyright © 2007 John Wiley & Sons, Ltd.
V
f
•1
II
i
r
s
€
\
_
1
VOLUME CONTENTS 2007
Volume 25 Issue Nos. 1^
HEMATOLOGICAL ONCOLOGY
VOLUME 25. ISSUE No. I March 2007
Research Articles
Myeloablative chemotherapy followed by autologous stem cell infusion may
overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine
kinase 3) mutations in patients with acute myeloid leukaemia and normal
karyotype
S Palmieri, F Ferrara, F Leoni, S Ciolli, F Pollio, MR D’Amico, M Celentano, A Viola,
L Vicari, B Izzo and F Pane. I
Relevance of Ras gene mutations in the context of the molecular heterogeneity
of multiple myeloma
D Intini, L Agnelli, G Ciceri, D Ronchetti, S Fabris, L Nobili, G Lambertenghi-Deliliers,
L Lombardi and A Neri. 6
Fertility among female hodgkin lymphoma survivors attempting pregnancy
following ABVD chemotherapy
DC Hodgson, M Pintilie, L Gitterman, B DeWitt, C-A Buckley, S Ahmed, K Smith,
A Schwartz, RW Tsang, M Crump, W Wells, A Sun and MK Gospodarowicz. II
Osteopontin dysregulation and lytic bone lesions in multiple myeloma
DF Robbiani, K Colon, S Ely, S Ely, M Chesi and PL Bergsagel. 15
Global correlation of genome and transcriptome changes in classical Hodgkin
lymphoma
J Kluiver, K Kok, I Pfeil, D de Jong, T BlokzijI, G Harms, P van der Vlies, A Diepstra,
^ Atayar, S Poppema, R Kiippers and A van den Berg. 21
Inhibition of Flt3-activating mutations does not prevent constitutive activation
of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited
effectiveness of monotherapy with small-molecule inhibitors
E Siendones, N Barbarroja, LA Torres, P Buendia, F Velasco, G Dorado, A Torres
and C Lopez-Pedrera. 30
The role of MDR-related proteins in the prognosis of adult acute myeloid
leukaemia (AML) with normal karyotype
D Damiani, M Tiribelli, D Raspadori, A Michelutti, A Gozzetti, E Calistri, A Candoni,
A Chiarvesio, M Lenoci, D Russo and R Fanin. 38
Current Awareness in Hematological Oncology. 44
VOLUME 25. ISSUE No. 2 june 2007
Review Articles
Review: New biological insights in early clinical studies
M Maur and C Sessa. 53
A review of the therapeutic agents used in the management of
polycythaemia vera
MF McMullin. 58
Therapeutic targets in chronic myeloid leukaemia
NB Heaney and TL Holyoake. 66
Research Articles
Interpretation of interleukin-2 receptor alpha positive cells during induction
chemotherapy for adult acute myelogenous leukaemia patients
W-S Min, H-J Kim, Y Choi, H-Y Jeong and C-C Kim. 76
Age has no influence on mobilization of peripheral blood stem cells in acute
myeloid leukemia
F Ferrara, A Viola, C Copia, C Falco, R D'elia, FP Tambaro, P Correale,
MR D'amico, L Vicari and S Palmieri. 84
Ig VH gene mutation status and genomic imbalances in chronic lymphocytic
leukaemia with increased prolymphocytes (CLU/PL)
Z Balogh, L Reiniger, L Deak, C Bodor, J Csomor, A Szepesi, E Gagyi,
L Kopper and A Matolcsy. 90
Perspective
Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention
using current anti-retroviral inhibitors such as ritonavir and nelfinavir
RE Kast, KF Foley and D Focosi. 96
Current Awareness in Hematological Oncology. 98
VOLUME 25, ISSUE No. 3 September 2007
Research Articles
A phase II study of a THP-COP regimen for the treatment of elderly patients
aged 70 years or older with diffuse large B-cell lymphoma
H Tsurumi, T Hara, N Goto, N Kanemura, S Kasahara, M Sawada, I Yasuda, T Yamada,
M Shimizu, T Takami and H Moriwaki. 107
Analysis of risk factors predicting thrombotic and/or haemorrhagic
complications in 306 patients with Essential Thrombocythemia
F Radaelli, M Colombi, R Calori, VR Zilioli, S Bramanti, A lurlo and A Zanella. 115
Prognostic relevance of circulating matrix metalloproteinase-2 in acute myeloid
leukaemia patients
S Aref, E Osman, S Mansy, N Omer, E Azmy, T Goda and M El-Sherbiny. 121
Rituximab monotherapy is highly effective in splenic marginal zone lymphoma
C Kalpadakis , GA Pangalis, MN Dimopoulou, TP Vassilakopoulos, M-C Kyrtsonis,
P Korkolopoulou,FN Kontopidou, MP Siakantaris, EM Dimitriadou, SI Kokoris,
P Tsaftaridis, E Plata and MK Angelopoulou. 127
Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and
dexamethasone) in patients with advanced multiple myeloma and historical
comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone)
G Hutter, H Szelenyiy, A Schmittel, JM Siehl, E Thiel and U Keilholz. 132
Case Reports
Senile EBV-associated B-cell lymphoproliferative disorder of prepatellar bursa
in an elderly patient with multifocal urate arthropathy
S Mueller, T Aigner, J Haag, R Schwarz and G Niedobitek. 140
First and second line imatinib treatment in chronic myelogenous leukemia
patients expressing rare e I a2 or e 19a2 BCR-ABL transcripts
H Andrikovics, S Nahajevszky, A Szilv^i, A Bors, E Adam, A Kozma, B Kajtar,
A Barta, A Poros and A Tordai. 143
Current Awareness in Hematological Oncology 148
VOLUME 25, ISSUE No. 4 December 2007
Review Article
Primary mediastinal B-cell lymphoma
E Boleti and PWM Johnson. 157
Research Articles
Patients with bisphosphonates-associated osteonecrosis of the jaw have
reduced circulating endothelial cells
A Allegra, G Oteri, E Nastro, A Alonci, G Bellomo, V Del Fabro, E Quartarone,
C Alati, FS De Ponte, D Cicciu and C Musolino. 164
Prognostic factors for patients with acute myeloid leukaemia or high-risk
myelodysplastic syndromes undergoing myeloablative or non-myeloablative
allogeneic blood stem cell transplantation
T Graef, M Vaupel, R Fenk, L Ruf, F Zohren, U Germing, R Haas and G Kobbe. 170
What is the Price of survival in Hodgkin's lymphoma? Long-term follow-up of
cured patients
M Zsofia, K Katalin, V judit, S Gyorgy and I Arpad. 178
Chromosome instability and translocation t( 11; 18) in primary gastric marginal
zone B-cell lymphoma of MALT-type
MG Tibiletti, K Milani, V Martin, E Zucca, T Motta, S Cortelazzo, G Pinotti,
L Mazzucchelli, G Pruned, G Martinelli, R Barbazza, C Capella and F Bertoni. 184
Incidence, clinical characteristics and survival of malignant lymphomas: a
population-based study from a cancer registry in northern Italy
S Luminari, M Cesaretti, I Rashid, C Mammi, A Montanini, E Barbolini, M Bellei,
E Pennese, MA Sirotti, L Marcheselli, G Partesotti, A Bari, A Maiorana,
G Bonacorsi and M Federico. 189
Liposome-encapsulated doxorubicin in combination with cyclophosphamide,
vincristine, prednisone and rituximab in patients with lymphoma and
concurrent cardiac diseases or pre-treated with anthracyclines
L Rigacci, S Mappa, L Nassi, R Alterini, V Carrai, F Bernardi and A Bosi. 198
Current Awareness in Hematological Oncology. 204
Author Index 2007. 212
Keyword Index 2007. 213
Volume Contents 2007 . iii